Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar:233:116793.
doi: 10.1016/j.bcp.2025.116793. Epub 2025 Feb 6.

Linoleic acid metabolism is implicated in the anti-obesity effects of actein in C57BL/6 mice

Affiliations

Linoleic acid metabolism is implicated in the anti-obesity effects of actein in C57BL/6 mice

Juan Chen et al. Biochem Pharmacol. 2025 Mar.

Abstract

Natural products are known to be a rich source of potential compounds for metabolic diseases. In this study, we aim to identify the lead compounds with anti-adipogenic and anti-obesity effects in Cimicifuga foetida L. (CF). Five high-content chemicals from ethyl acetate extract of CF (ECF) were isolated to investigate their effects on adipogenesis in 3T3-L1 preadipocytes. Actein is identified to possess substantial anti-adipogenic activity in 3T3-L1 adipocytes, which exerts its anti-adipogenic effect throughout the entire adipocyte differentiation stages. Dietary actein ameliorates diet-induced obesity, improves the disturbed serum lipid levels, and enhances white fat browning in diet-induced obese mice. Metabolomic analysis using urine and serum samples from mice revealed that actein treatment reverses the dysregulation of γ-linolenic acid and lecithin in obese mice, thus ameliorating the disturbance of linoleic acid metabolism induced by high-fat diet, suggesting that actein can be used as a lead compound with the potential to develop new therapies for obesity and related metabolic disorders.

Keywords: Actein; Adipocyte browning; Cimicifuga foetida L.; Linoleic acid metabolism; Metabolomics; Obesity.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Publication types